RT Journal Article
SR Electronic
T1 Addressing Extreme Imbalance for Detecting Medications Mentioned in Twitter User Timelines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.09.21251453
DO 10.1101/2021.02.09.21251453
A1 Weissenbacher, Davy
A1 Rawal, Siddharth
A1 Magge, Arjun
A1 Gonzalez-Hernandez, Graciela
YR 2021
UL http://medrxiv.org/content/early/2021/02/12/2021.02.09.21251453.abstract
AB Tweets mentioning medications are valuable for efforts in digital epidemiology to supplement traditional methods of monitoring public health. A major obstacle, however, is to differentiate them from the large majority of tweets on other topics posted in a user’s timeline: solving the infamous ‘needle in a haystack’ problem. While deep learning models have significantly improved classification, their performance and inference processing time remain low on extremely imbalanced corpora where the tweets of interest are less than 1% of all tweets. In this study, we empirically evaluate under-sampling, fine-tuning, and filtering heuristics to train such classifiers. Using a corpus of 212 Twitter timelines (181,607 tweets with only 0.2% tweets mentioning a medication), our results show that combining these heuristics is necessary to impact the classifier’s performance. In our intrinsic evaluation, a classifier based on a lexicon and a BERT-base neural network achieved a 0.838 F1-score, a score similar to the ones of the best existing classifier, but it processed the corpus 28 times faster - a positive result, since processing speed is still a roadblock to deploying classifiers on large cohorts of Twitter users needed for pharmacovigilance. In our extrinsic evaluation, our classifier helped a labeler to extract the spans of medications more accurately and achieved a 0.76 Strict F1-score. To the best of our knowledge, this is the first evaluation of medications extraction in Twitter timelines and it establishes the first benchmark for future studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Library of Medicine grant number R01LM011176 to GG-H. The content is solely the responsibility of the authors and does not necessarily represent the official view of National Library of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A certificate of exemption was obtained from the Institutional Review Board of the University of PennsylvaniaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be released during the BioCreative VII shared-tasks https://tinyurl.com/fo9u9xnn